GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » Degree of Operating Leverage

IOBT (IO Biotech) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is IO Biotech Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. IO Biotech does not have enough data to calculate Degree of Operating Leverage.


IO Biotech Degree of Operating Leverage Historical Data

The historical data trend for IO Biotech's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech Degree of Operating Leverage Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial - - - - -

IO Biotech Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IO Biotech's Degree of Operating Leverage

For the Biotechnology subindustry, IO Biotech's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IO Biotech's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IO Biotech's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where IO Biotech's Degree of Operating Leverage falls into.


;
;

IO Biotech Degree of Operating Leverage Calculation

IO Biotech's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -97.564 (Mar. 2025) / -93.716 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=0.0411/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


IO Biotech  (NAS:IOBT) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


IO Biotech Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of IO Biotech's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


IO Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Executives
Qasim Iftikhar Ahmad officer: Chief Medical Officer 1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan officer: Chief Financial Officer 38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
Mai-britt Zocca director, officer: Chief Executive Officer 1209 ORANGE STREET, WILMINGTON DE 19801
Devin Whittemore Smith officer: General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Brian Burkavage officer: Chief Accounting Officer C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma 10 percent owner 24 RUE ROYALE, PARIS I0 75008
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
David V Smith director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Claus A. Andersson director 1209 ORANGE STREET, WILMINGTON DE 19801